Notice to convene Evaxion’s Annual General Meeting
Rhea-AI Summary
Evaxion (NASDAQ: EVAX) has convened its Annual General Meeting for April 16, 2026 at 14:00 CET to be held at the company's offices in Hørsholm, Denmark. The agenda and meeting materials are available on the company's investor website, and investor contact details are provided for further questions.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
EVAX was down 1.31% while momentum peers like GOVX and IBIO showed gains of 4.8% and 3.2%, suggesting today’s move was more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 05 | Earnings and update | Positive | +9.3% | Full-year 2025 results with stronger finances and major partnership wins. |
| Mar 05 | Filing timing update | Neutral | +9.3% | Slight delay to 2025 annual report filing due to technical vendor issues. |
| Mar 02 | Earnings date set | Neutral | +0.3% | Announcement of date and call details for full-year 2025 results. |
| Jan 13 | AI platform expansion | Positive | -1.5% | Expansion of AI-Immunology™ into autoimmune with cash runway unchanged. |
| Jan 07 | Conference presentation | Positive | +6.7% | Planned 2026 milestones presentation at Biotech Showcase conference. |
Recent substantive updates (earnings, milestones) often saw positive price reactions, while one strategic AI expansion update drew a mild negative response, indicating occasional divergence on otherwise constructive news.
In the last six months, Evaxion released several milestone updates. On Mar 5, 2026, full-year 2025 results and a business update, including improved finances and partnerships, coincided with a +9.32% move. An AI-Immunology™ platform expansion on Jan 13, 2026 led to a modest -1.54% reaction. Conference and scheduling announcements around Jan 7, 2026 and Mar 2, 2026 produced smaller but generally positive moves. Today’s AGM notice fits the non-fundamental governance category within this backdrop.
Market Pulse Summary
This announcement convenes Evaxion’s Annual General Meeting for April 16, 2026 at the company’s Danish offices, a routine corporate governance step without new financial or clinical data. In recent months, more material events—like 2025 results, partnership progress, and AI-Immunology™ expansion—have driven the fundamental story. Investors may focus on upcoming milestones and any proposals or board matters presented at the AGM for incremental signals.
AI-generated analysis. Not financial advice.
COPENHAGEN, Denmark, March 19, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces that its Annual General Meeting is convened to be held on April 16, 2026, at 14.00 CET.
The meeting will be held at the company’s offices, Dr Neergaards Vej 5F, 2970 Hørsholm, Denmark.
The agenda and proposals can be found on Evaxion’s website, along with other materials:
www.evaxion.ai/investors/events-presentations/annual-general-meeting-2026/
Contact information
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai
About Evaxion
Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.
With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development
We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.
For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website.
Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.
FAQ
When is Evaxion's (EVAX) Annual General Meeting scheduled for 2026?
Where will Evaxion's (EVAX) April 16, 2026 AGM be held?
How can shareholders access Evaxion (EVAX) AGM agenda and materials for April 16, 2026?
Who should investors contact for questions about Evaxion's (EVAX) April 16, 2026 AGM?
Do Evaxion (EVAX) shareholders need to register before the April 16, 2026 AGM?
